Emerging Drug Developer: Ambit Biosciences
Emerging Drug Developer: Ambit Biosciences
Ambit Biosciences has taken another important step forward. In the middle of last month, CEO Scott Salka announced that it had garnered about $50 million in its fourth round. That money should be enough to get the company through 2009, a key transition period for Ambit. "We're expecting at least clinical proof of concept and completion of that milestone with one compound by the end of '09." Salka tells FierceBiotech, which named Ambit a Fierce 15 company in 2006. Article
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
